Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | HTT | P42858 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | XBP1 | P17861 | 2/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865228 | 0.86 | KMT2A (0.59) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL3429585 | 0.84 | MAPT (0.68) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL19252045 | 0.82 | MEN1 (0.66) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL30101230 | 0.82 | KMT2A (0.90) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL5597699 | 0.82 | KMT2A (0.90) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL12989341 | 0.82 | LMNA (0.71) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL3433781 | 0.81 | TP53 (0.64) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL4548162 | 0.80 | KMT2A (0.87) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL14855582 | 0.80 | MAPT (0.70) | MAPTMEN1KMT2AHTTRAB9A | |
| SCHEMBL14685427 | 0.80 | MAPT (0.66) | MAPTMEN1KMT2AHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B9 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-10-21 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3464273-B1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | CHIESI FARM SPA (IT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3464269-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE | CHIESI FARM SPA (IT) | 2020-04-01 | — | — | EP | disclosed |
| EP-3464269-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464273-A1 | IMIDAZOLONE COMPOUNDS AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| EP-3233833-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| US-10023558-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-07-17 | — | — | US | disclosed |
| WO-2016096638-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20160168101-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-06-16 | — | — | US | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-01 | — | — | US | disclosed |
| EP-1873159-A1 | Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
| EP-1873159-A1 | Substituted sulphonamido-macrocycles as Tie2 inhibitors and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007147575-A2 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISINGS SAME, METHODS OF PREPARING SAME AND USES SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023558-B2 | Compounds | SERPINB1, ELANE, MPO | MAPT 3506/4885MEN1 3964/4885KMT2A 3935/4885 |
| US-20160168101-A1 | NOVEL COMPOUNDS | ELANE, SERPINB1, MPO | MAPT 4309/4885MEN1 4140/4885KMT2A 4210/4885 |
| US-20090005373-A1 | SUBSTITUTED SULFONAMIDO-MACROCYCLES AS TIE2 INHIBITORS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | TIE1, KDR, TEK | MAPT 2698/4885MEN1 480/4885KMT2A 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.